LncRNA RP1-86C11.7 [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======  LncRNA RP1-86C11.7  ======


The [[transferrin]] receptor is a [[membrane glycoprotein]] whose only clearly defined function is to mediate cellular uptake of [[iron]] from a plasma glycoprotein, transferrin.

Glioblastoma (Glioblastoma) remains the most common and malignant tumor of the human central nervous system. Increasing evidence has highlighted that tumor cells with high [[transferrin receptor]] (TFRC) expression show advantages in growth. [[Long noncoding RNA]]s ([[lncRNA]]s) are related to [[glioma progression]] by mediating [[microRNA]]s [[(miRNA]]s). However, the underlying mechanism among TFRC, miRNA and lncRNA in Glioblastoma is limited. 

Ma et al. identified a new lncRNA-induced signaling mechanism that regulates the [[transferrin receptor]] (TFRC) levels in Glioblastoma (Glioblastoma). The TFRC level was higher in [[glioma cell line]]s, and elevated TFRC expression promoted the proliferation and survival of [[glioma cell]]s. Further study showed that hsa-miR-144a-3p bound to the 3'-UTR of TFRC mRNA and inhibited its expression, preventing the malignant properties of glioma cells, such as [[proliferation]] and [[survival]]. They also found that the lncRNA RP1-86C11.7 sponges hsa-miR-144-3p to suppress its protective role in [[glioma]]. RP1-86C11.7 overexpression in glioma cells elevated TFRC expression, increased the intracellular free [[iron]] level, and deteriorated [[oncogenicity]], with a significant reduction in hsa-miR-144-3p. By contrast, silencing RP1-86C11.7 upregulated the hsa-miR-144-3p level, resulting in decreased TFRC expression and repressed glioma progression. However, the effect of silencing RP1-86C11.7 was reversed with simultaneous hsa-miR-144-3p inhibitor treatment: the TFRC level, intracellular iron level and proliferation in glioma cells increased. Mechanistically, this data indicated that RP1-86C11.7 exacerbates the malignant behavior of glioma through the hsa-miR-144-3p/TFRC axis. RP1-86C11.7 may be a potential [[biomarker]] or target to treat glioma in the future
((Ma Q, Wang X, Li J. [[LncRNA RP1-86C11.7]] exacerbates the [[glioma progression]] and [[oncogenicity]] by [[hsa-miR-144]]-3p/TFRC signaling. Transl Oncol. 2021 Sep 24;14(12):101215. doi: 10.1016/j.tranon.2021.101215. Epub ahead of print. PMID: 34571345.)).